ProfileGDS5678 / 1418373_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 81% 86% 67% 68% 69% 68% 68% 67% 68% 70% 68% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0836467
GSM967853U87-EV human glioblastoma xenograft - Control 25.8693881
GSM967854U87-EV human glioblastoma xenograft - Control 36.4697486
GSM967855U87-EV human glioblastoma xenograft - Control 44.1015167
GSM967856U87-EV human glioblastoma xenograft - Control 54.1039968
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2385569
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1987868
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1360468
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1199767
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1480268
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3036270
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1323568
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1484168
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1566268